Breast Cancer Res Treat
Breast Cancer Research and Treatment
0167-6806
1573-7217
Springer US
Boston


2001220
17912640
9697
10.1007/s10549-007-9697-2
Review


®
 and the future: tailoring treatment and combination therapies with Femara

Ellis
Matthew

+1-314-3623774
+1-314-3627086
mellis@wustl.edu



Ma
Cynthia



Medical Oncology, Washington University, 660 Euclid Ave, Campus Box 8056, St Louis, MO 63110 USA 

3
10
2007

10
2007

105
Suppl 1
105
115
3
1
2007

17
7
2007


© Springer Science+Business Media, LLC 2007

Long-term estrogen deprivation treatment for breast cancer can, in some patients, lead to the activation of alternate cellular pathways, resulting in the re-emergence of the disease. This is a distressing scenario for oncologists and patients, but recent intensive molecular and biochemical studies are beginning to unravel these pathways, revealing opportunities for new targeted treatments. Far from making present therapies redundant, these new discoveries open the door to novel combination therapies that promise to provide enhanced efficacy or overcome treatment resistance. Letrozole, one of the most potent aromatase inhibitors, is the ideal candidate for combination therapy; indeed, it is one of the most intensively studied aromatase inhibitors in the evolving combinatorial setting. Complementary to the use of combination therapy is the development of molecular tools to identify patients who will benefit the most from these new treatments. Microarray gene profiling studies, designed to detect letrozole-responsive targets, are currently under way to understand how the use of the drug can be tailored more efficiently to specific patient needs.

Keywords
Adjuvant therapy
Aromatase inhibitors
Breast cancer
Combination therapy
Letrozole
Mechanism of resistance
Postmenopausal

issue-copyright-statement
© Springer Science+Business Media, LLC. 2007




Introduction
1
2
3
4
5
].
6
7
10
]. Greater understanding of tumor biology is beginning to help physicians to individualize treatment selection based on clinical, pathologic, molecular, and genetic profiling, and to rationally design novel combinations to improve efficacy and safety.
®
; Novartis Pharmaceuticals) in combination strategies with agents targeting other growth factor pathways. The review explores the hypothesis that combining letrozole with specifically targeted therapies may delay or overcome endocrine therapy resistance in postmenopausal women with hormone receptor-positive (HR+) breast cancer.

Endocrine therapy resistance
11
12
13
12
13
].
13
14
15
16
14
19
15
19
].

Growth factor pathways
20
21
22
15
23
25
4
4
7
4
4
].
26
27
4
28
].

Combination therapy
1
29
30
HER2
31
32
18
33
34
35
Fig. 1
thick black arrow
gray arrows
Stars 
AI 
SERD 
MoAb 
TKI 
FTI 
CCI 
28
] with permission from the American Association for Cancer Research




36
37
38
4
39
39
37
40
41
41
41
42
43
43
].
44
45
44
46
47
48
3
49
].
1
52
3
39
53
18
46
54
4
35
50
55
56
Table 1
Summary of letrozole in combination with growth factor signaling inhibitors in preclinical models

Target for growth factor inhibitor
Combination regimen
Summary of key findings
References


EGFR/HER2
Letrozole + AEE78
Combination enhanced antiproliferative effects in MCF-7 (ER+ HER2−), ZR75.1 (ER+ HER2+), and BT474 (ER+ HER2+) cell lines
42
]

Partial restoration of growth inhibitory effects of letrozole in refractory cell lines (LTLT-Ca; long-term letrozole treated)
43
]

mTOR
Letrozole + RAD001 (everolimus)
Letrozole + RAD001 significantly increased apoptosis compared with either agent alone
50
]

Co-treatment increased sensitivity to letrozole in resistant MCF-7 cells with constitutively active Akt
48
]

RAD001 increased antiproliferative effects of letrozole in MCF-7 Arom 1 cell line
47
]

IGFBP
Letrozole + rhIGFBP-3
rhIGFBP-3 Enhanced letrozole activity in MCF-7-Ca cells in vitro and in vivo
51
]



rhIGFBP recombinant human insulin-like growth factor binding protein



57
58
12
1
).

Clinical trials of letrozole in combination with inhibitors of growth factor signaling pathways
2
Table 2
Clinical studies of letrozole and inhibitors of growth factor signaling pathways

Target for growth factor inhibitor
Combination regimen
Study type and patient population
Summary of key findings
References


HER2
Letrozole + trastuzumab

n
 = 31)
ORR 26%; median TTP 5.8 months
59
]

EGFR/HER2
Letrozole + lapatinib

n
 = 36)
Letrozole + lapatinib safely combined at recommended single agent doses
60
]


n
 = 1,200 target accrual)
Ongoing trial; primary end point TTP
61
]

mTOR
Letrozole + RAD-001 (everolimus)

n
 = 6)
RAD001 pharmacokinetics not altered by letrozole
62
]


n
 = 255 planned)
Ongoing trial of efficacy and biomarkers
63
]

Letrozole + CCI-779 (temsirolimus)

n
 = 92)
No difference in ORR, but trend to longer PFS with letrozole + temsirolimus (30 mg)
64
]


n
 = 1,236 planned)
Terminated
65
]

Farnesyl transferase
Letrozole + tipifarnib 

n
 = 121)
ORR 38% for letrozole and 26% for letrozole + tipifarnib (NS)
66
]


n
 = 120)
No longer recruiting
67
]

VEGF
Letrozole + bevacizumab (anti-VEGF monoclonal antibody)

n
 = 28)
Letrozole + bevacizumab is well-tolerated
54
]

Endocrine therapy (tamoxifen or aromatase inhibitor) + bevacizumab

n
 = TBC)
Planned trial
54
]

Bcr-abl
Letrozole + imatinib

n
 = 15)
Letrozole + imatinib is feasible
68
]



BC 
ORR 
TTP 
PFS 
AI 
TBC 
to be confirmed



69
54
70
54
71
71
2
54
Fig. 2
Planned CALGB trial of first-line endocrine therapy (tamoxifen or aromatase inhibitor) with or without bevacizumab




59
59
60
61
3
63
Fig. 3
Letrozole and lapatinib phase III trial design. Target recruitment: 1,280 patients




72
]. The hypothesis-generating study found that three of ten patients demonstrated ER overexpression at 9, 12, and 37 weeks, respectively, following the initiation of trastuzumab. Two of these patients were subsequently treated with endocrine therapy alone and one received letrozole for 3 years without evidence of progression. Further trials of letrozole used in combination with trastuzumab or sequentially in patients with HER2+, ER− tumors appear warranted.

Microarray/gene profiling studies and optimization of treatment with letrozole
73
74
], potentially expediting clinical development. Therefore, identifying biomarkers that predict endocrine resistance is essential for the optimal use of letrozole. In addition, biomarker studies that help to delineate the oncogenic pathways may be particularly useful for the development of novel combination therapies with letrozole.
75
77
78
79
80
80
81
82
83
84
85
84
]. Advances in gene profiling will provide further insights into tumor biology and improve prediction of likely response to specific therapies in the clinic.
86
87
N
N
87
88
89
89
].
90
89
91
92
] is comparing hormone therapy with or without combination chemotherapy as adjuvant therapy for node-negative, ER+ breast cancer. The objective of this randomized phase III trial is to determine the best individual therapy using Oncotype DX gene profiling.
93
]. This offers an opportunity to identify pathway-specific drugs in endocrine therapy-resistant tumors and creates an opportunity for the rational design of combination therapy with letrozole. In addition to the RNA-based gene expression profiling approach, high throughput analysis at the DNA level, such as genome-wide microarray comparative genomic hybridization (aCGH) and DNA sequencing, has made it possible to decipher the genetic anomalies that drive a particular tumor phenotype. The use of these molecular approaches for biomarker development is still in its infancy but is now feasible with recent advances in genomic technologies.

Conclusions
Hormone-sensitive breast cancer can be regarded as a chronic disease with a persistent risk of escape from effective endocrine control. Activation of growth factor signaling pathways has been implicated in progression of HR+ breast cancer to an estrogen-independent phenotype and the development of resistance to endocrine therapy, particularly tamoxifen. It has been hypothesized that combining endocrine therapy with targeted signal transduction inhibitors may circumvent hormone-independent signaling pathways, so that patients may experience prolonged disease control.
HER2
 gene amplification) and represents an ideal combination partner for agents that inhibit growth signaling pathways implicated in hormone resistance. The efficacy of letrozole is currently being investigated with a variety of signal transduction inhibitors with different mechanisms of action, including monoclonal antibodies against HER family receptors, receptor tyrosine kinase inhibitors, and downstream signaling pathway inhibitors.
Gene expression profiling has been validated as a useful new tool to predict risk of relapse in patients treated with hormone therapy and chemotherapy. This approach will help physicians to identify which patient will likely benefit from specific therapies, such as letrozole. Tailoring therapy to individual patient profiles (clinical, histologic, pathologic, and genetic) will become more sophisticated in the future, helping to maximize the benefits of endocrine therapy throughout the breast cancer continuum; letrozole will undoubtedly become an integral part of the next generation of tailored combination regimens for the treatment of breast cancer.


References
1.
Lacroix
M

Toillon
RA

Leclercq
G


Stable ‘portrait’ of breast tumors during progression: data from biology, pathology and genetics
Endocr Relat Cancer
2004
11
497
522
10.1677/erc.1.00758

15369451


2.
Robertson
JF


Oestrogen receptor: a stable phenotype in breast cancer
Br J Cancer
1996
73
5
12

8554983


3.
Brodie
A

Jelovac
D

Sabnis
G

Long
B

Macedo
L

Goloubeva
O


Model systems: mechanisms involved in the loss of sensitivity to letrozole
J Steroid Biochem Mol Biol
2005
95
41
48
10.1016/j.jsbmb.2005.04.026

15967659


4.
Shou
J

Massarweh
S

Osborne
CK

Wakeling
AE

Ali
S

Weiss
H

Schiff
R


Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer
J Natl Cancer Inst
2004
96
926
935

15199112


5.
Konecny
G

Pauletti
G

Pegram
M

Untch
M

Dandekar
S

Aguilar
Z

Wilson
C

Rong
HM

Bauerfeind
I

Felber
M

Wang
HJ

Beryt
M

Seshadri
R

Hepp
H

Slamon
DJ


Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer
J Natl Cancer Inst
2003
95
142
153

12529347


6.
Shaw
LE

Sadler
AJ

Pugazhendhi
D

Darbre
PD


Changes in oestrogen receptor-alpha and -beta during progression to acquired resistance to tamoxifen and fulvestrant (Faslodex, ICI 182,780) in MCF7 human breast cancer cells
J Steroid Biochem Mol Biol
2006
99
19
32
10.1016/j.jsbmb.2005.11.005

16533599


7.
Osborne
CK

Bardou
V

Hopp
TA

Chamness
G

Hilsenbeck
SG

Fuqua
SA

Wong
J

Allred
DC

Clark
GM

Schiff
R


Role of estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer
J Natl Cancer Inst
2003
95
353
361

12618500


8.
Kirkegaard
T

Witton
CJ

McGlynn
LM

Tovey
SM

Dunne
B

Lyon
A

Bartlett
JM


AKT activation predicts outcome in breast cancer patients treated with tamoxifen
J Pathol
2005
207
139
146
10.1002/path.1829

16088978


9.
Shin
I

Miller
T

Arteaga
CL


ErbB receptor signaling and therapeutic resistance to aromatase inhibitors
Clin Cancer Res
2006
12
1008s
1012s
10.1158/1078-0432.CCR-05-2352

16467117


10.
Arpino
G

Weiss
H

Lee
AV

Schiff
R

Placido
S

Osborne
CK

Elledge
RM


Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance
J Natl Cancer Inst
2005
97
1254
1261

16145046


11.
Masamura
S

Santner
SJ

Heitjan
DF

Santen
RJ


Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells
J Clin Endocrinol Metab
1995
80
2918
2925
10.1210/jc.80.10.2918

7559875


12.
Berstein
LM

Wang
JP

Zheng
H

Yue
W

Conaway
M

Santen
RJ


Long-term exposure to tamoxifen induces hypersensitivity to estradiol
Clin Cancer Res
2004
10
1530
1534
10.1158/1078-0432.CCR-0433-03

14977857


13.
Santen
RJ

Song
RX

Zhang
Z

Kumar
R

Jeng
MH

Masamura
S

Lawrence
J

MacMahon
LP

Yue
W

Berstein
L


Adaptive hypersensitivity to estrogen: mechanisms and clinical relevance to aromatase inhibitor therapy in breast cancer treatment
J Steroid Biochem Mol Biol
2005
95
155
165
10.1016/j.jsbmb.2005.04.025

16024245


14.
Santen
RJ

Song
RX

Zhang
Z

Kumar
R

Jeng
MH

Masamura
A

Lawrence
J

Berstein
L

Yue
W


Long-term estradiol deprivation in breast cancer cells up-regulates growth factor signaling and enhances estrogen sensitivity
Endocr Relat Cancer
2005
12
Suppl 1
S61
S73
10.1677/erc.1.01018

16113100


15.
Jeng
MH

Yue
W

Eischeid
A

Wang
JP

Santen
RJ


Role of MAP kinase in the enhanced cell proliferation of long term estrogen deprived human breast cancer cells
Breast Cancer Res Treat
2000
62
167
175
10.1023/A:1006406030612

11072781


16.
Yue
W

Wang
JP

Conaway
M

Masamura
S

Li
Y

Santen
RJ


Activation of the MAPK pathway enhances sensitivity of MCF-7 breast cancer cells to the mitogenic effect of estradiol
Endocrinology
2002
143
3221
3229
10.1210/en.2002-220186

12193533


17.
Martin
LA

Farmer
I

Johnston
SR

Ali
S

Marshall
C

Dowsett
M


Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation
J Biol Chem
2003
278
30458
30468
10.1074/jbc.M305226200

12775708


18.
Knowlden
JM

Hutcheson
IR

Jones
HE

Madden
T

Gee
JM

Harper
ME

Barrow
D

Wakeling
AE

Nicholson
RI


Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells
Endocrinology
2003
144
1032
1044
10.1210/en.2002-220620

12586780


19.
Yue
W

Wang
J

Li
Y

Fan
P

Santen
RJ


Farnesylthiosalicylic acid blocks mammalian target of rapamycin signaling in breast cancer cells
Int J Cancer
2005
117
746
754
10.1002/ijc.21222

15957161


20.
Song
RX

McPherson
RA

Adam
L

Bao
Y

Shupnik
M

Kumar
R

Santen
RJ


Linkage of rapid estrogen action to MAPK activation by ERalpha-Shc association and Shc pathway activation
Mol Endocrinol
2002
16
116
127
10.1210/me.16.1.116

11773443


21.
Clark
JH

Peck
EJ


Nuclear retention of receptor–oestrogen complex and nuclear acceptor sites
Nature
1976
260
635
637
10.1038/260635a0

177882


22.
Li
L

Haynes
MP

Bender
JR


Plasma membrane localization and function of the estrogen receptor alpha variant (ER46) in human endothelial cells
Proc Natl Acad Sci USA
2003
100
4807
4812
10.1073/pnas.0831079100

12682286


23.
Wong
CW

McNally
C

Nickbarg
E

Komm
BS

Cheskis
BJ


Estrogen receptor-interacting protein that modulates its nongenomic activity-crosstalk with Src/Erk phosphorylation cascade
Proc Natl Acad Sci USA
2002
99
14783
14788
10.1073/pnas.192569699

12415108


24.
Filardo
EJ

Quinn
JA

Bland
KI

Frackelton
AR


Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via transactivation of the epidermal growth factor receptor through release of HB-EGF
Mol Endocrinol
2000
14
1649
1660
10.1210/me.14.10.1649

11043579


25.
Filardo
EJ

Quinn
JA

Frackelton
AR

Bland
KI


Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis
Mol Endocrinol
2002
16
70
84
10.1210/me.16.1.70

11773440


26.
Howell
A

Dowsett
M


Endocrinology, hormone therapy in breast cancer: aromatase inhibitors versus antioestrogens
Breast Cancer Res
2004
6
269
274
10.1186/bcr945

15535858


27.
Osborne
CK

Schiff
R


Aromatase inhibitors: future directions
J Steroid Biochem Mol Biol
2005
95
183
187
10.1016/j.jsbmb.2005.04.021

16019204


28.
Johnston
SR


Combinations of endocrine and biological agents: present status of therapeutic and presurgical investigations
Clin Cancer Res
2005
11
889s
899s

15701883


29.
Fendly
BM

Winget
M

Hudziak
RM

Lipari
MT

Napier
MA

Ullrich
A


Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product
Cancer Res
1990
50
1550
1558

1689212


30.
Carter
P

Presta
L

Gorman
CM

Ridgway
JB

Henner
D

Wong
WL

Rowland
AM

Kotts
C

Carver
ME

Shepard
HM


Humanization of an anti-p185HER2 antibody for human cancer therapy
Proc Natl Acad Sci USA
1992
89
4285
4289
10.1073/pnas.89.10.4285

1350088


31.
Slamon
DJ

Godolphin
W

Jones
LA

Holt
JA

Wong
SG

Keith
DE

Levin
WJ

Stuart
SG

Udove
J

Ullrich
A



Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
Science
1989
244
707
712
10.1126/science.2470152

2470152


32.
Witters
L

Engle
L

Lipton
A


Restoration of estrogen responsiveness by blocking the HER-2/neu pathway
Oncol Rep
2002
9
1163
1166

12375012


33.
Nahta
R

Hung
MC

Esteva
FJ


The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells
Cancer Res
2004
64
2343
2346
10.1158/0008-5472.CAN-03-3856

15059883


34.
Adams
CW

Allison
DE

Flagella
K

Presta
L

Clarke
J

Dybdal
N

McKeever
K

Sliwkowski
MX


Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab
Cancer Immunol Immunother
2006
55
717
727
10.1007/s00262-005-0058-x

16151804


35.
Argiris
A

Wang
CX

Whalen
SG

DiGiovanna
MP


Synergistic interactions between tamoxifen and trastuzumab (Herceptin)
Clin Cancer Res
2004
10
1409
1420
10.1158/1078-0432.CCR-1060-02

14977844


36.
King
CR

Borrello
I

Bellot
F

Comoglio
P

Schlessinger
J


Egf binding to its receptor triggers a rapid tyrosine phosphorylation of the erbB-2 protein in the mammary tumor cell line SK-BR-3
EMBO J
1988
7
1647
1651

2901952


37.
Moulder
SL

Yakes
FM

Muthuswamy
SK

Bianco
R

Simpson
JF

Arteaga
CL


Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo
Cancer Res
2001
61
8887
8895

11751413


38.
Sabnis
GJ

Jelovac
D

Long
B

Brodie
A


The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation
Cancer Res
2005
65
3903
3910
10.1158/0008-5472.CAN-04-4092

15867390


39.
Gee
JM

Harper
ME

Hutcheson
IR

Madden
TA

Barrow
D

Knowlden
JM

McClelland
RA

Jordan
N

Wakeling
AE

Nicholson
RI


The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro.
Endocrinology
2003
144
5105
5117
10.1210/en.2003-0705

12960029


40.
Xia
W

Mullin
RJ

Keith
BR

Liu
LH

Ma
H

Rusnak
DW

Owens
G

Alligood
KJ

Spector
NL


Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways
Oncogene
2002
21
6255
6263
10.1038/sj.onc.1205794

12214266


41.
Konecny
GE

Pegram
MD

Venkatesan
N

Finn
R

Yang
G

Rahmeh
M

Untch
M

Rusnak
DW

Spehar
G

Mullin
RJ

Keith
BR

Gilmer
TM

Berger
M

Podratz
KC

Slamon
DJ


Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells
Cancer Res
2006
66
1630
1639
10.1158/0008-5472.CAN-05-1182

16452222


42.
Hauge-Evans AC, Evans DB, Dowsett M, Martin L-A (2004) Combining the RTK inhibitor AEE788 with tamoxifen or letrozole results in enhanced growth inhibition of hormone-dependent human breast cancer cells. Presented at the 27th Annual San Antonio Breast Cancer Symposium, 8–11 December 2004. Abstract 308

43.
Sabnis GJ, Jelovac D, Long BJ, Schayowitz A, Belosay A, Brodie AMH (2006) Mammalian target of rapamycin (mTOR) as a target in human breast cancer cells that have acquired resistance to aromatase inhibitor letrozole. Poster presented at the proceedings of the 97th American Association for Cancer Research Annual Meeting, Washington, DC, 1–5 April 2006. Abstract 2316

44.
Kelland
LR

Smith
V

Valenti
M

Patterson
L

Clarke
PA

Detre
S

End
D

Howes
AJ

Dowsett
M

Workman
P

Johnston
SR


Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer
Clin Cancer Res
2001
7
3544
3550

11705875


45.
Clark
GJ

Der
CJ


Aberrant function of the Ras signal transduction pathway in human breast cancer
Breast Cancer Res Treat
1995
35
133
144
10.1007/BF00694753

7612899


46.
Yu
K

Toral-Barza
L

Discafani
C

Zhang
WG

Skotnicki
J

Frost
P

Gibbons
JJ


mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer
Endocr Relat Cancer
2001
8
249
258
10.1677/erc.0.0080249

11566616


47.
Farmer
I

Evans
DB

Lane
HA

Lykkesfeldt
AE

Dowsett
M

Martin
L


Preclinical studies of the combination of RAD001 with tamoxifen or letrozole in breast cancer
Eur J Cancer
2006
4
2 Suppl
142

Farmer I, Evans DB, Lane HA, Lykkesfeldt AE, Dowsett M, Martin L (2006) Preclinical studies of the combination of RAD001 with tamoxifen or letrozole in breast cancer. Eur J Cancer 4(2 Suppl):142. Abstract 324 

48.
Silva JM, Lin Y, Nielsen A, Friedrichs WE, Beeram M, Tekmal R et al (2006) RAD001 relieves Akt-induced suppression of the ASK/JNK pathway in resistant breast cancer cells. In: Abstracts of the 97th American Association for Cancer Research Annual Meeting, Washington, DC, 1–5 April 2006. Abstract 5068

49.
Jelovac
D

Sabnis
G

Long
BJ

Macedo
L

Goloubeva
OG

Brodie
AM


Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole
Cancer Res
2005
65
5380
5389
10.1158/0008-5472.CAN-04-4502

15958587


50.
Boulay
A

Rudloff
J

Ye
J

Zumstein-Mecker
S

O’Reilly
T

Evans
DB

Chen
S

Lane
HA


Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer
Clin Cancer Res
2005
11
5319
5328
10.1158/1078-0432.CCR-04-2402

16033851


51.
Alami
N

Banerjee
K

Page
V

Brossard
M

Shiry
L

Brodie
A

Leyland-Jones
B


Synergistic interaction between recombinant human insulin-like growth factor-binding protein 3 (rhIGFBP-3) and letrozole in estrogen positive breast cancer
Breast Cancer Res Treat
2005
94
Suppl 1
S234

Alami N, Banerjee K, Page V, Brossard M, Shiry L, Brodie A, Leyland-Jones B (2005) Synergistic interaction between recombinant human insulin-like growth factor-binding protein 3 (rhIGFBP-3) and letrozole in estrogen positive breast cancer. Breast Cancer Res Treat 94(Suppl 1):S234. Abstract 5081 

52.
Nicholson
RI

Hutcheson
IR

Hiscox
SE

Knowlden
JM

Giles
M

Barrow
D

Gee
JM


Growth factor signaling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of anti-growth factor therapies to treat or delay endocrine resistance in breast cancer
Endocr Relat Cancer
2005
12
Suppl 1
S29
S36
10.1677/erc.1.00991

16113097


53.
Massarweh
S

Shou
J

Mohsin
SK

Ge
M

Wakeling
AE

Osborne
CK

Schiff
R


Inhibition of epidermal growth factor/HER2 receptor signaling using ZD1839 (“Iressa”) restores tamoxifen sensitivity and delays resistance to estrogen deprivation in HER2-overexpressing breast tumors
J Clin Oncol
2002
21
33a

Massarweh S, Shou J, Mohsin SK, Ge M, Wakeling AE, Osborne CK, Schiff R (2002) Inhibition of epidermal growth factor/HER2 receptor signaling using ZD1839 (“Iressa”) restores tamoxifen sensitivity and delays resistance to estrogen deprivation in HER2-overexpressing breast tumors. J Clin Oncol 21:33a. Abstract 130 

54.
Traina
TA

Rugo
H

Caravelli
J

Yeh
B

Panageas
K

Bruckner
J

Norton
L

Park
J

Hudis
C

Dickler
M


Letrozole (L) with bevacizumab (B) is feasible in patients (pts) with hormone receptor-positive metastatic breast cancer (MBC)
J Clin Oncol
2006
24
18S
133s

Traina TA, Rugo H, Caravelli J, Yeh B, Panageas K, Bruckner J, Norton L, Park J, Hudis C, Dickler M (2006) Letrozole (L) with bevacizumab (B) is feasible in patients (pts) with hormone receptor-positive metastatic breast cancer (MBC). J Clin Oncol 24(18S):133s. Abstract 3050 

55.
Doisneau-Sixou
SF

Cestac
P

Faye
JC

Favre
G

Sutherland
RL


Additive effects of tamoxifen and the farnesyl transferase inhibitor FTI-277 on inhibition of MCF-7 breast cancer cell-cycle progression
Int J Cancer
2003
106
789
798
10.1002/ijc.11263

12866041


56.
Rudloff
J

Boulay
A

Zumstein-Mecker
S

Evans
DB

O’Reilly
T

Lane
HA


®
) in breast carcinomas
Proc Am Assoc Cancer Res
2004
45
1298

Rudloff J, Boulay A, Zumstein-Mecker S, Evans DB, O’Reilly T, Lane HA (2004) The mTOR pathway in estrogen response: a potential for combining the rapamycin derivative RAD001 with the aromatase inhibitor letrozole (Femara®) in breast carcinomas. Proc Am Assoc Cancer Res 45:1298. Abstract 5619 

57.
Mass
RD

Press
MF

Anderson
S

Cobleigh
MA

Vogel
CL

Dybdal
N

Leiberman
G

Slamon
DJ


Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab
Clin Breast Cancer
2005
6
240
246

16137435


58.
Ji
H

Zhao
X

Yuza
Y

Shimamura
T

Li
D

Protopopov
A

Jung
BL

McNamara
K

Xia
H

Glatt
KA

Thomas
RK

Sasaki
H

Horner
JW

Eck
M

Mitchell
A

Sun
Y

Al-Hashem
R

Bronson
RT

Rabindran
SK

Discafani
CM

Maher
E

Shapiro
GI

Meyerson
M

Wong
KK


Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors
Proc Natl Acad Sci USA
2006
103
7817
7822
10.1073/pnas.0510284103

16672372


59.
Marcom
PK

Isaacs
C

Harris
L

Wong
ZW

Kommarreddy
A

Novielli
N

Mann
G

Tao
Y

Ellis
MJ


The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers
Breast Cancer Res Treat
2007
102
1
43
49
10.1007/s10549-006-9307-8

16897431


60.
Chu
Q

Goldstein
L

Murray
N

Rowinsky
E

Cianfrocca
M

Gale
M

Ho
P

Paul
E

Loftiss
J

Pandite
L


A phase I, open-label study of the safety, tolerability and pharmacokinetics of lapatinib (GW572016) in combination with letrozole in cancer patients
J Clin Oncol
2005
23
16S
192s

Chu Q, Goldstein L, Murray N, Rowinsky E, Cianfrocca M, Gale M, Ho P, Paul E, Loftiss J, Pandite L (2005) A phase I, open-label study of the safety, tolerability and pharmacokinetics of lapatinib (GW572016) in combination with letrozole in cancer patients. J Clin Oncol 23(16S):192s. Abstract 3001 

61.
http://www.clinicaltrials.gov/show/NCT00073528
. Cited 25 Aug 2006

62.
Awada
A

Cardoso
F

Fontaine
C

Dirix
L

Grève
J

Sotiriou
C

Steinseifer
J

Wouters
C

Tanaka
C

Ressayre-Djaffer
C

Piccart
M


®
), investigating safety and pharmacokinetics in patients with advanced breast cancer stable or slowly progressing on letrozole
Breast Cancer Res Treat
2004
88
Suppl 1
S234

Awada A, Cardoso F, Fontaine C, Dirix L, De Grève J, Sotiriou C, Steinseifer J, Wouters C, Tanaka C, Ressayre-Djaffer C, Piccart M (2004) A phase Ib study of the mTOR inhibitor RAD001 (everolimus) in combination with letrozole (Femara®), investigating safety and pharmacokinetics in patients with advanced breast cancer stable or slowly progressing on letrozole. Breast Cancer Res Treat 88(Suppl 1):S234. Abstract 6043 

63.
http://www.clinicaltrials.gov/ct/show/NCT00107016
. Cited 25 Aug 2006

64.
Baselga
J

Roché
H

Fumoleau
P

Campone
M

Colomer
R

Cortes-Funes
H

Gil
M

Chan
S

Boni
J

Kong
S

Cincotta
M

Moore
L


Treatment of postmenopausal women with locally advanced or metastatic breast cancer with letrozole alone or in combination with temsirolimus: a randomized, 3-arm, phase 2 study
Breast Cancer Res Treat
2005
94
Suppl 1
S62

Baselga J, Roché H, Fumoleau P, Campone M, Colomer R, Cortes-Funes H, Gil M, Chan S, Boni J, Kong S, Cincotta M, Moore L (2005) Treatment of postmenopausal women with locally advanced or metastatic breast cancer with letrozole alone or in combination with temsirolimus: a randomized, 3-arm, phase 2 study. Breast Cancer Res Treat 94(Suppl 1):S62. Abstract 1068 

65.
http://www.clinicaltrials.gov/show/NCT00083993
. Cited 25 Aug 2006

66.
®
) combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy. Breast Cancer Res Treat 94(Suppl 1):S237. Abstract 5087

67.
http://www.clinicaltrials.gov/show/NCT00050141
. Cited 25 Aug 2006

68.
Aun
B

Dice
K

ALbarracin
C

Rivera
E

Walters
R

Theriault
R

Booser
D

Bast
R

Cristofanili
M

Sahin
A

Smith
TL

Hortobagyi
GN


The combination of letrozole and imatinib mesylate for metastatic breast cancer
Breast Cancer Res Treat
2004
88
Suppl 1
S235

Aun B, Dice K, ALbarracin C, Rivera E, Walters R, Theriault R, Booser D, Bast R, Cristofanili M, Sahin A, Smith TL, Hortobagyi GN (2004) The combination of letrozole and imatinib mesylate for metastatic breast cancer. Breast Cancer Res Treat 88(Suppl 1):S235. Abstract 6046 

69.
http://www.clinicaltrials.gov/show/NCT00305825
. Cited 25 Aug 2006

70.
Mouridsen
H

Gershanovich
M

Sun
Y

Perez-Carrion
R

Boni
C

Monnier
A

Apffelstaedt
J

Smith
R

Sleeboom
HP

Jaenicke
F

Pluzanska
A

Dank
M

Becquart
D

Bapsy
PP

Salminen
E

Snyder
R

Chaudri-Ross
H

Lang
R

Wyld
P

Bhatnagar
A


Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group
J Clin Oncol
2003
21
2101
2109
10.1200/JCO.2003.04.194

12775735


71.
Rugo
HS

Dickler
MN

Traina
TA

Scott
JH

Moore
DH

Bruckner
J

Hudis
C

Park
JW


Change in circulating endothelial cells (CEC) predicts progression free survival (PFS) in patients (pts) with hormone receptor positive metastatic breast cancer (MBC) receiving letrozole (L) and bevacizumab (B)
J Clin Oncol
2006
24
18S
130s

Rugo HS, Dickler MN, Traina TA, Scott JH, Moore DH, Bruckner J, Hudis C, Park JW (2006) Change in circulating endothelial cells (CEC) predicts progression free survival (PFS) in patients (pts) with hormone receptor positive metastatic breast cancer (MBC) receiving letrozole (L) and bevacizumab (B). J Clin Oncol 24(18S):130s. Abstract 3039 

72.
Munzone
E

Curigliano
G

Rocca
A

Bonizzi
G

Renne
G

Goldhirsch
A

Nole
F


Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy
Breast Cancer Res
2006
8
R4
10.1186/bcr1366

16417653


73.
http://www.fda.gov/bbs/topics/news/2006/NEW01316.html
. Cited 22 Aug 2006

74.
Dowsett M, A’Hern R, Smith I et al on behalf of the IMPACT Trialists (2005) Ki67 after 2 weeks’ endocrine treatment predicts relapse-free survival (RFS) in the IMPACT trial. Presented at the 28th Annual San Antonio Breast Cancer Symposium, 8–11 December 2005. Abstract 45

75.
Perou
CM

Sorlie
T

Eisen
MB

Rijn
M

Jeffrey
SS

Rees
CA

Pollack
JR

Ross
DT

Johnsen
H

Akslen
LA

Fluge
O

Pergamenschikov
A

Williams
C

Zhu
SX

Lonning
PE

Borresen-Dale
AL

Brown
PO

Botstein
D


Molecular portraits of human breast tumours
Nature
2000
406
747
752
10.1038/35021093

10963602


76.
Sorlie
T

Perou
CM

Tibshirani
R

Aas
T

Geisler
S

Johnsen
H

Hastie
T

Eisen
MB

Rijn
M

Jeffrey
SS

Thorsen
T

Quist
H

Matese
JC

Brown
PO

Botstein
D

Eystein Lonning
P

Borrensen-Dale
AL


Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
Proc Natl Acad Sci USA
2001
98
10869
10874
10.1073/pnas.191367098

11553815


77.
Sorlie
T

Tibshirani
R

Parker
J

Hastie
T

Marron
JS

Nobel
A

Deng
S

Johnsen
H

Pesich
R

Geisler
S

Demeter
J

Perou
CM

Lonning
PE

Brown
PO

Borrensen-Dale
AL

Botstein
D


Repeated observation of breast tumor subtypes in independent gene expression data sets
Proc Natl Acad Sci USA
2003
100
8418
8423
10.1073/pnas.0932692100

12829800


78.
Wang
Y

Klijn
JG

Zhang
Y

Sieuwerts
AM

Look
MP

Yang
F

Talantov
D

Timmermans
M

Meijer-van Gelder
ME

Yu
J

Jatkoe
T

Berns
EM

Atkins
D

Foekens
JA


Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer
Lancet
2005
365
671
679

15721472


79.
Vijver
MJ

He
YD

van’t Veer
LJ

Dai
H

Hart
AA

Voskuil
DW

Schreiber
GJ

Peterse
JL

Roberts
C

Marton
MJ

Parrish
M

Atsma
D

Witteveen
A

Glas
A

Delahaye
L

Velde
T

Bartelink
H

Rodenhius
S

Rutgers
ET

Friend
SH

Bernards
R


A gene-expression signature as a predictor of survival in breast cancer
N Engl J Med
2002
347
1999
2009
10.1056/NEJMoa021967

12490681


80.
Paik
S

Shak
S

Tang
G

Kim
C

Baker
J

Cronin
M

Baehner
FL

Walker
MG

Watson
D

Park
T

Hiller
W

Fisher
ER

Wickerman
DL

Bryant
J

Wolmark
N


A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
N Engl J Med
2004
351
2817
2826
10.1056/NEJMoa041588

15591335


81.
Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Watson D, Bryant J, Costantino J, Wolmark N (2005) Expression of the 21 genes in the recurrence score assay and tamoxifen clinical benefit in the NSABP study B-14 of node negative, estrogen receptor positive breast cancer. J Clin Oncol 23(16S):6s. Abstract 510

82.
Paik
S

Tang
G

Shak
S

Kim
C

Baker
J

Kim
W

Cronin
M

Baehner
FL

Watson
D

Bryant
J

Costantino
JP

Geyer
CE

Wickerman
DL

Wolmark
N


Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer
J Clin Oncol
2006
24
3726
3734
10.1200/JCO.2005.04.7985

16720680


83.
Naderi
A

Teschendorff
AE

Barbosa-Morais
NL

Robertson
JFR

Ellis
IO

Brenton
JD

Caldas
C


Robust identification of novel prognostic gene-signatures in breast cancer
Eur J Cancer
2006
4
2 Suppl
135

Naderi A, Teschendorff AE, Barbosa-Morais NL, Robertson JFR, Ellis IO, Brenton JD, Caldas C (2006) Robust identification of novel prognostic gene-signatures in breast cancer. Eur J Cancer 4(2 Suppl):135. Abstract 300 

84.
Naderi
A

Teschendorff
A

Beigel
J

Cariati
M

Ellis
I

Brenton
J

Caldas
C


Bex2 identifies a novel subtype of breast cancer associated with estrogen-response and NGF/NFKB pathway
Eur J Cancer
2006
4
2 Suppl
125

Naderi A, Teschendorff A, Beigel J, Cariati M, Ellis I, Brenton J, Caldas C (2006) Bex2 identifies a novel subtype of breast cancer associated with estrogen-response and NGF/NFKB pathway. Eur J Cancer 4(2 Suppl):125. Abstract 267 

85.
Laere
S

Auwera
I

Eynden
G

Huygelen
V

Elst
H

Dam
P

Marck
E

Vermeulen
P

Dirix
L


Inflammatory breast cancer: at the cross-roads of NFkB and estrogen receptor signalling pathways?
Eur J Cancer
2006
4
2 Suppl
136

Van Laere S, Van der Auwera I, Van den Eynden G, Huygelen V, Elst H, van Dam P, Van Marck E, Vermeulen P, Dirix L (2006) Inflammatory breast cancer: at the cross-roads of NFkB and estrogen receptor signalling pathways? Eur J Cancer 4(2 Suppl):136. Abstract 305 

86.
Miller
WR

Renshaw
L

Larionov
A

Anderson
TJ

White
S

Hampton
G

Walker
JR

Ho
S

Krause
A

Evans
DB

Dixon
MJ


Prediction of hormone response in breast cancer by microarray analysis of sequential tumour biopsies from patients receiving neoadjuvant therapy with letrozole
J Clin Oncol
2005
23
16S
198S

Miller WR, Renshaw L, Larionov A, Anderson TJ, White S, Hampton G, Walker JR, Ho S, Krause A, Evans DB, Dixon MJ (2005) Prediction of hormone response in breast cancer by microarray analysis of sequential tumour biopsies from patients receiving neoadjuvant therapy with letrozole. J Clin Oncol 23(16S):198S. Abstract 3025 

87.
Miller
W

Renshaw
L

Larionov
A

Anderson
T

White
S

Hampton
G



Using changes in gene expression as assessed by microarray analysis of sequential tumour biopsies to predict response to neoadjuvant therapy with letrozole
Eur J Cancer
2006
4
2 Suppl
129

Miller W, Renshaw L, Larionov A, Anderson T, White S, Hampton G et al (2006) Using changes in gene expression as assessed by microarray analysis of sequential tumour biopsies to predict response to neoadjuvant therapy with letrozole. Eur J Cancer 4(2 Suppl):129. Abstract 282 

88.
Urruticoechea
A

Dowsett
M

Mackay
A

Dexter
T

Young
O

Miller
WR

Evans
DB

Dixon
GM


Molecular characterisation of ER+ breast cancer before and during treatment with the aromatase inhibitors, letrozole and anastrozole
J Clin Oncol
2005
23
16S
850S

Urruticoechea A, Dowsett M, Mackay A, Dexter T, Young O, Miller WR, Evans DB, Dixon GM (2005) Molecular characterisation of ER+ breast cancer before and during treatment with the aromatase inhibitors, letrozole and anastrozole. J Clin Oncol 23(16S):850S. Abstract 9554 

89.
Itoh
T

Karlsberg
K

Kijima
I

Yuan
YC

Smith
D

Ye
J

Chen
S


Letrozole-, anastrozole-, and tamoxifen-responsive genes in MCF-7aro cells: a microarray approach
Mol Cancer Res
2005
3
203
218

15831674


90.
Frasor
J

Danes
JM

Komm
B

Chang
KC

Lyttle
CR

Katzenellenbogen
BS


Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype
Endocrinology
2003
144
4562
4574
10.1210/en.2003-0567

12959972


91.
van ’t Veer
LJ


Molecular strategies improve therapeutic decisions
Eur J Cancer
2006
4
2 Suppl
2

van ’t Veer LJ (2006) Molecular strategies improve therapeutic decisions. Eur J Cancer 4(2 Suppl):2. Extended Abstract E1 

92.
http://www.clinicaltrials.gov/ct/show/NCT00310180
. Cited 25 Aug 2006

93.
Bild
AH

Yao
G

Chang
JT

Wang
Q

Potti
A

Chasse
D

Joshi
MB

Harpole
D

Lancaster
JM

Berchuck
A

Olson
JA

Marks
JR

Dressman
HK

West
M

Nevins
JR


Oncogenic pathway signatures in human cancers as a guide to targeted therapies
Nature
2006
439
353
357
10.1038/nature04296

16273092



http://dx.doi.org/10.1007/s10549-007-9856-5





